生长分化因子15：口腔癌中一种有前景的生物标志物。
Growth differentiation factor 15: a promising biomarker in oral cancer.
作者信息
Oh Hyun Jun, Lee Jong-Ho, Kim Soung Min
机构信息
Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea.
出版信息
J Korean Assoc Oral Maxillofac Surg. 2025 Apr 30;51(2):123-125. doi: 10.5125/jkaoms.2025.51.2.123.
Abstract
Growth differentiation factor 15 (GDF-15), a cytokine within the transforming growth factor-β superfamily, is involved in various malignancies, with implications in oral squamous cell carcinoma (OSCC). Elevated GDF-15 levels are correlated with unfavorable prognosis, tumor progression, and chemotherapy resistance, and the protein has been identified as a potential diagnostic and prognostic biomarker for OSCC. Personalized treatment strategies based on GDF-15 expression could improve treatment outcomes.
摘要
生长分化因子15（GDF-15）是转化生长因子-β超家族中的一种细胞因子，参与多种恶性肿瘤，与口腔鳞状细胞癌（OSCC）有关。GDF-15水平升高与不良预后、肿瘤进展和化疗耐药相关，该蛋白已被确定为OSCC的一种潜在诊断和预后生物标志物。基于GDF-15表达的个性化治疗策略可能会改善治疗效果。
相似文献
1
Growth differentiation factor 15: a promising biomarker in oral cancer.
J Korean Assoc Oral Maxillofac Surg. 2025 Apr 30;51(2):123-125. doi: 10.5125/jkaoms.2025.51.2.123.
2
GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma.
Oral Oncol. 2012 Jul;48(7):608-14. doi: 10.1016/j.oraloncology.2012.01.020. Epub 2012 Feb 16.
3
Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by Analysis of Differential Gene Expression.
Curr Pharm Des. 2024;30(4):310-322. doi: 10.2174/0113816128276149240108163407.
4
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions.
Int J Gynecol Cancer. 2010 Dec;20(9):1448-55. doi: 10.1111/IGC.0b013e3181f7d6be.
5
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer.
BMC Cancer. 2024 Aug 5;24(1):954. doi: 10.1186/s12885-024-12727-3.
6
Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
J Oral Pathol Med. 2014 Jan;43(1):28-34. doi: 10.1111/jop.12091. Epub 2013 May 26.
7
Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma.
Biomolecules. 2021 Dec 7;11(12):1842. doi: 10.3390/biom11121842.
8
Growth differentiation factor 15 as a radiation-induced marker in oral carcinoma increasing radiation resistance.
J Oral Pathol Med. 2016 Jan;45(1):63-9. doi: 10.1111/jop.12323. Epub 2015 Apr 16.
9
Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.
BMC Cancer. 2012 Aug 1;12:332. doi: 10.1186/1471-2407-12-332.
10
Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Int J Mol Sci. 2020 Mar 29;21(7):2360. doi: 10.3390/ijms21072360.
本文引用的文献
1
Ponsegromab for the Treatment of Cancer Cachexia.
N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14.
2
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer.
BMC Cancer. 2024 Aug 5;24(1):954. doi: 10.1186/s12885-024-12727-3.
3
Salivary biomarkers for early detection of oral squamous cell carcinoma (OSCC) and head/neck squamous cell carcinoma (HNSCC): A systematic review and network meta-analysis.
Jpn Dent Sci Rev. 2024 Dec;60:32-39. doi: 10.1016/j.jdsr.2023.10.003. Epub 2023 Dec 21.
4
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
Clin Cancer Res. 2024 Feb 1;30(3):489-497. doi: 10.1158/1078-0432.CCR-23-1631.
5
Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review).
Oncol Rep. 2023 Dec;50(6). doi: 10.3892/or.2023.8650. Epub 2023 Oct 20.
6
Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype.
Cancer Lett. 2022 Jun 28;536:215664. doi: 10.1016/j.canlet.2022.215664. Epub 2022 Mar 26.
7
Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.
Cytokine Growth Factor Rev. 2022 Apr;64:71-83. doi: 10.1016/j.cytogfr.2021.11.002. Epub 2021 Nov 17.
8
Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
Cancer Sci. 2022 Feb;113(2):478-488. doi: 10.1111/cas.15218. Epub 2021 Dec 20.
9
Identification and validation of potential novel biomarkers for oral squamous cell carcinoma.
Bioengineered. 2021 Dec;12(1):8845-8862. doi: 10.1080/21655979.2021.1987089.
10
The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
Annu Rev Physiol. 2021 Feb 10;83:127-151. doi: 10.1146/annurev-physiol-022020-045449. Epub 2020 Nov 23.
Zotero 插件